Meningococcal C conjugate vaccine: the experience in England and Wales.
about
How the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective Neisseria meningitidis VaccinesThe role of seroepidemiology in the comprehensive surveillance of vaccine-preventable diseasesThe impact of new vaccine introduction on immunization and health systems: a review of the published literatureA Novel Loop-Mediated Isothermal Amplification Assay for Serogroup Identification of Neisseria meningitidis in Cerebrospinal FluidImmunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trialEpidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccinationDoes post-implementation vaccine effectiveness data support pre-implementation predictions of 4CMenB utility?Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada.Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunityGlobal practices of meningococcal vaccine use and impact on invasive disease.Evaluation of the induction of immune memory following infant immunisation with serogroup C Neisseria meningitidis conjugate vaccines--exploratory analyses within a randomised controlled trial.Clonal analysis of meningococci during a 26 year period prior to the introduction of meningococcal serogroup C vaccines.Changes in serogroup and genotype prevalence among carried meningococci in the United Kingdom during vaccine implementationSeroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009Single nucleotide polymorphisms in the Toll-like receptor 3 and CD44 genes are associated with persistence of vaccine-induced immunity to the serogroup C meningococcal conjugate vaccine.Pneumococcal genome sequencing tracks a vaccine escape variant formed through a multi-fragment recombination event.Meningococcal disease serogroup C.Invasive meningococcal capsular group Y disease, England and Wales, 2007-2009.Risk of invasive meningococcal disease in children and adults with HIV in England: a population-based cohort study.Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country.Meningococcal Carriage in Military Recruits and University Students during the Pre MenB Vaccination Era in Greece (2014-2015)Development of a high-throughput method to evaluate serum bactericidal activity using bacterial ATP measurement as survival readoutEffectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England.Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the NetherlandsVaccines for the prevention of meningococcal capsular group B disease: What have we recently learned?Impact of vaccination on meningococcal epidemiologyReduction in Neisseria meningitidis infection in Italy after Meningococcal C conjugate vaccine introduction: A time trend analysis of 1994-2012 series.Meningococcal group B vaccines.Evaluation of the impact of serogroup C meningococcal disease vaccination program in Brazil and its regions: a population-based study, 2001-2013Bioanalysis of meningococcal vaccines.Optimizing the acceptability, effectiveness and costs of immunization programs: the Quebec experience.Meningococcal disease: shifting epidemiology and genetic mechanisms that may contribute to serogroup C virulence.New frontiers in meningococcal vaccines.Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers.Changing epidemiology of meningococcal disease in Europe from the mid-20th to the early 21st Century.MenACWY-TT vaccine for active immunization against invasive meningococcal disease.Glycoconjugate vaccines.Quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT): a review.Evolving meningococcal immunization strategies.
P2860
Q26782340-4FF8B6B7-A320-4BB1-BBC9-F1AAA8A59E3AQ26824389-5F5AAE8F-3DCE-4A8A-A57B-0EB3383E786EQ27009450-1D0C443C-FDEA-4B81-9213-9F62E7D1F514Q28602719-472FBA78-F200-475B-954D-C72F8493C9A7Q28650557-E1951CBA-BAF8-46C7-8145-AFA4965DBA02Q28659784-C2AC9B17-CD6A-4F66-9E15-8F3D719762FEQ30235138-148C9EE5-1E4C-4638-BB60-99157A23175EQ33637512-F94B61B2-558A-492D-9F6D-0D174B7DF07DQ33825722-8D056E74-E641-4659-B449-D84079812EB5Q33850840-F160611D-EB47-409C-8655-E87F7B112866Q33895627-F8049769-EB43-44F9-A419-BADD1A1CD2CBQ35006862-B0770536-D129-451A-A26C-9B330623FA23Q35188450-52D6FB64-7FF4-406F-ACD8-AA54087C8305Q35739057-6AF1283F-3F2D-461C-A46A-F23FC7DBF03FQ35805284-FED78B66-B25B-4860-92E1-0A56CFFBF16CQ35828374-3ABFD700-9A87-42F8-BDA9-F2E6CAE557F8Q35832179-22857990-0579-43EE-8D58-B45FFC72E84FQ35845900-24180BA7-FB6F-4CD7-BEAA-9C656A7B7F3DQ35865540-60CFE48C-E6E6-40A9-858D-AAC85853F9BFQ35887288-B449C00A-4B12-4491-A29F-C196023F72F4Q35887617-099B0F02-309E-455E-B165-7FEA1EF23228Q36210154-854142AF-B40E-4B53-B7C4-0C607690DF28Q36278608-84C0664E-103A-4C99-A38F-AC715FF10A8BQ36525220-568CF046-D0D7-4145-9783-FE5CF911CDDEQ36891586-DA08CFEF-5408-4485-9AE4-95DD69FE94A1Q37130205-160DFBA4-35CC-4F95-A8D3-30A9E1B27639Q37130791-F7F40A07-CC2D-4737-B2D1-ACC9EC71EE94Q37309285-44734F68-A986-42C8-B57B-F23CAEEDE152Q37514834-1897E950-D823-4964-85A8-8E6DE9AA780DQ37705727-FCEB0615-20AE-47D0-BFCB-13DC99A08E76Q37810253-EAD61C23-6E6C-4461-80F4-9D8489BD76DDQ37821482-C70CB9EB-F798-4652-81C8-4B5659B77418Q37878375-EABA1FE9-AEEA-4135-9685-D1DBAF532A9FQ37878480-10AEE355-0EFA-45CD-91DD-7C528EE8F45AQ37909415-D1B910EF-B498-4D44-9760-840C6C796C7DQ37944323-B8FDD8E9-35F8-4665-AE41-C565268EC0B4Q38028992-833610B4-803C-4BF6-A8C9-A43C848E881DQ38044755-1B21ED7C-29CB-462B-8450-72189C2B4A37Q38118371-951FADE7-EC31-4050-8E6D-5C5FBEB1BD01Q38286082-BAB902A2-BF39-427E-8C37-F7FDF9DDDBE5
P2860
Meningococcal C conjugate vaccine: the experience in England and Wales.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Meningococcal C conjugate vaccine: the experience in England and Wales.
@en
Meningococcal C conjugate vaccine: the experience in England and Wales.
@nl
type
label
Meningococcal C conjugate vaccine: the experience in England and Wales.
@en
Meningococcal C conjugate vaccine: the experience in England and Wales.
@nl
prefLabel
Meningococcal C conjugate vaccine: the experience in England and Wales.
@en
Meningococcal C conjugate vaccine: the experience in England and Wales.
@nl
P2093
P1433
P1476
Meningococcal C conjugate vaccine: the experience in England and Wales.
@en
P2093
David Salisbury
Elizabeth Miller
Helen Campbell
P356
10.1016/J.VACCINE.2009.04.067
P407
P478
27 Suppl 2
P50
P577
2009-05-23T00:00:00Z